Can Running Reduce Fatty Liver?

Can running reduce fatty liver? Evidence suggests it can. Regular aerobic exercise, including running, has been shown in clinical studies to meaningfully reduce liver fat in people with non-alcoholic fatty liver disease (NAFLD), now also referred to as metabolic dysfunction-associated steatotic liver disease (MASLD). Importantly, these benefits can occur even without significant weight loss, as the liver responds directly to exercise as a metabolic stimulus. This article explains how running affects liver fat, how much you need to do, what NHS and NICE guidance says, and how to exercise safely if you have liver disease.

Can running actually reduce a fatty liver?

Yes, running can meaningfully reduce liver fat in NAFLD/MASLD, with clinical studies showing benefits from regular aerobic exercise even when body weight does not change substantially.

Yes, running can meaningfully reduce liver fat in people with non-alcoholic fatty liver disease (NAFLD), now increasingly referred to in clinical and research settings as metabolic dysfunction-associated steatotic liver disease (MASLD). The two terms describe the same condition; NHS and NICE publications still commonly use NAFLD, and both terms are used here for clarity. What was previously called non-alcoholic steatohepatitis (NASH) is now termed metabolic dysfunction-associated steatohepatitis (MASH) in newer consensus documents, though NHS and NICE pages may still use NASH.

Multiple clinical studies and systematic reviews have demonstrated that regular aerobic exercise, including running, reduces hepatic fat content even when body weight does not change substantially. This is an important distinction: the liver responds to exercise as a metabolic stimulus in its own right, not solely as a consequence of weight loss.

NAFLD/MASLD is the most common chronic liver condition in the UK. The British Liver Trust estimates that around one in three people in the UK has some degree of fatty liver, though prevalence figures vary depending on the diagnostic method and population studied. The condition ranges from simple steatosis (fat accumulation without significant inflammation) through to MASH (formerly NASH), fibrosis and, in a minority of cases, cirrhosis. Lifestyle intervention, including structured physical activity, is the cornerstone of management recommended by NICE (guideline NG49).^[1][2]

Running is a practical and accessible form of aerobic exercise that raises heart rate, increases energy expenditure and promotes fat oxidation in multiple tissues, including the liver. For people who are new to exercise or have comorbidities such as type 2 diabetes or obesity, it is advisable to speak with a GP before starting a running programme to ensure it is appropriate and safe.

How does aerobic exercise affect liver fat?

Aerobic exercise reduces liver fat by improving insulin sensitivity, increasing fatty acid oxidation and activating AMPK, with measurable reductions in liver fat seen after approximately eight to twelve weeks of consistent training.

Aerobic exercise is thought to reduce liver fat through several proposed mechanisms, supported by human trial data. These include increasing the rate at which the body oxidises (burns) fatty acids, reducing the supply of free fatty acids delivered to the liver from adipose tissue, and improving insulin sensitivity. When insulin resistance is present, the liver is exposed to chronically elevated levels of circulating fatty acids and insulin, both of which promote de novo lipogenesis (the conversion of carbohydrates into fat within the liver). Running and other aerobic activities are believed to interrupt this cycle by improving peripheral glucose uptake in skeletal muscle and reducing visceral adiposity.

At a cellular level, aerobic exercise is proposed to activate AMP-activated protein kinase (AMPK), an enzyme that acts as an energy sensor. AMPK activation is associated with suppression of fatty acid synthesis and promotion of fatty acid oxidation in the liver. Exercise has also been linked to reductions in markers of hepatic inflammation, including circulating pro-inflammatory cytokines. It is worth noting that the relationship between exercise and cytokines such as interleukin-6 is context-dependent: acute exercise transiently raises IL-6, whereas regular training is associated with lower basal inflammatory markers. These mechanisms are based on proposed pathways supported by human and animal research; the full picture in humans remains an active area of study.

Importantly, these metabolic benefits begin to accumulate relatively quickly. Randomised controlled trials using imaging-based measures of liver fat (such as MRI-derived proton density fat fraction) have shown measurable reductions in liver fat content after approximately eight to twelve weeks of consistent aerobic training. The magnitude of benefit appears to be related to the total volume of exercise performed, as well as intensity, with energy-expenditure matched protocols suggesting volume plays a particularly important role. It should be noted that while aerobic exercise consistently improves hepatic steatosis, histological improvements in MASH (inflammation and fibrosis) are less consistently demonstrated without accompanying weight loss.^[3]

How much running do you need to do to see a difference?

At least 150 minutes of moderate-intensity aerobic exercise per week is associated with clinically meaningful liver fat reduction, with some trials suggesting greater benefit at 250 to 300 minutes per week.

Current evidence suggests that achieving at least 150 minutes of moderate-intensity aerobic exercise per week is associated with clinically meaningful reductions in liver fat. This aligns with the UK Chief Medical Officers' Physical Activity Guidelines (2019), which recommend that adults accumulate at least 150 minutes of moderate-intensity activity, or 75 minutes of vigorous-intensity activity, each week.^[5][6] Running at a comfortable conversational pace qualifies as moderate intensity; running at a pace where speaking in full sentences becomes difficult qualifies as vigorous.

For those specifically targeting liver fat reduction, some randomised trials and meta-analyses have examined higher volumes of exercise, in the range of 250 to 300 minutes per week, and found greater reductions in hepatic steatosis. However, for individuals who are currently sedentary, starting with shorter sessions of 20 to 30 minutes three to four times per week and gradually increasing duration and frequency is a more sustainable and injury-conscious approach.

Consistency matters more than any single session. Research on detraining suggests that liver fat can begin to re-accumulate when regular exercise stops, so establishing a routine that can be maintained long-term is more beneficial than short bursts of intense activity. Combining running with resistance training may offer additional metabolic advantages, as muscle mass plays an important role in glucose disposal and insulin sensitivity, and this combination is supported by evidence for metabolic health outcomes. If you are unsure how to structure a programme, a GP or a qualified exercise professional can provide personalised guidance.

What does the NHS say about exercise and fatty liver disease?

NHS and NICE NG49 recommend regular physical activity and dietary change as the primary treatment for NAFLD/MASLD, as no licensed medication is currently available in the UK for this condition.

The NHS recommends lifestyle modification, including regular physical activity and dietary change, as the primary treatment for NAFLD/MASLD. There is currently no licensed medication specifically indicated for NAFLD/MASLD in the UK, though this is an evolving area and it is worth checking with your GP or specialist for the most up-to-date position.^[9][10] This makes exercise and diet the most evidence-based interventions currently available. NHS guidance and NICE NG49 emphasise that even modest improvements in fitness and a reduction in body weight of 5 to 10 per cent can lead to significant reductions in liver fat and inflammation, a finding supported by clinical trials and systematic reviews.^[13][1]

NICE guideline NG49 (Non-alcoholic fatty liver disease: assessment and management) supports the use of structured lifestyle programmes incorporating physical activity and recommends non-invasive fibrosis risk stratification in primary care. Tools such as the FIB-4 score or the NAFLD Fibrosis Score are used to identify people at higher risk of significant fibrosis, with further assessment using the Enhanced Liver Fibrosis (ELF) test or transient elastography (FibroScan) where indicated. People with scores suggesting higher risk are referred to a hepatologist or specialist liver service. It is also worth knowing that NAFLD/MASLD can occur with entirely normal liver function tests, so a normal blood result does not exclude the condition; ultrasound or specialist imaging may be needed.^[8]

GPs play a central role in identifying NAFLD, often through incidental findings on liver function tests or abdominal ultrasound. If you have been told you have a fatty liver, your GP can refer you to a hepatologist or a specialist liver service if there are concerns about disease progression. NHS-commissioned weight management services and structured exercise referral schemes may also be available through your local Integrated Care Board (ICB), though provision varies by area. It is worth asking your GP what is available locally.

Are there any risks to running if you already have liver disease?

Running is safe for most people with simple hepatic steatosis, but those with advanced or decompensated cirrhosis, or coexisting conditions such as type 2 diabetes or cardiovascular disease, should seek medical review before starting or intensifying exercise.

For the majority of people with simple hepatic steatosis or early-stage NAFLD/MASLD, running is safe and actively beneficial. However, certain situations warrant medical review before beginning or intensifying an exercise programme.

People with advanced liver disease should seek specialist advice before undertaking vigorous exercise. It is important to distinguish between compensated cirrhosis (where the liver is still functioning adequately) and decompensated cirrhosis (characterised by complications such as ascites, hepatic encephalopathy or a history of variceal bleeding). In decompensated cirrhosis, haemodynamic changes during intense activity may carry additional risks, and exercise should only be undertaken under specialist supervision.

If you experience any of the following, seek urgent medical attention rather than exercising: vomiting blood or passing black, tarry stools (which may indicate gastrointestinal bleeding), new or worsening confusion, fever with abdominal pain, or yellowing of the skin or eyes (jaundice). For chest pain or difficulty breathing during exercise, call 999 immediately. If you notice persistent right upper quadrant abdominal pain or unexplained fatigue after running, contact your GP.

Individuals with NAFLD frequently have coexisting conditions such as type 2 diabetes, cardiovascular disease or obesity, which may independently affect exercise safety. People with diabetes who are taking insulin or sulphonylureas should be aware of the risk of hypoglycaemia during prolonged aerobic activity.^[12] Practical steps include checking blood glucose before exercise, carrying fast-acting carbohydrate (such as glucose tablets or a sugary drink), and following NHS hypoglycaemia guidance. Those with cardiovascular risk factors may benefit from a pre-exercise assessment before starting a running programme.

Musculoskeletal injury is a practical risk for anyone new to running, particularly those who are overweight, as excess body weight increases the load on joints. Starting with brisk walking and gradually transitioning to running, using appropriate footwear, and allowing adequate recovery time between sessions can reduce this risk.

What else can you do alongside running to improve liver health?

A Mediterranean-style diet, alcohol reduction, resistance training and good sleep quality all complement running and address the metabolic drivers of fatty liver disease.

Running is most effective when combined with broader lifestyle changes that address the metabolic drivers of fatty liver disease. Dietary modification is particularly important. A Mediterranean-style dietary pattern, characterised by high intake of vegetables, wholegrains, legumes, oily fish, nuts and olive oil, with limited ultra-processed foods, refined carbohydrates and added sugars, has the strongest evidence base for liver health in NAFLD/MASLD, supported by randomised trials and systematic reviews.^[16][17] This pattern is broadly consistent with NHS Eatwell Guide principles.

Alcohol consumption should be minimised or avoided entirely. Even in people with NAFLD/MASLD (which by definition is not caused by alcohol), alcohol places additional metabolic burden on the liver and can accelerate disease progression. For people with advanced fibrosis or cirrhosis, abstinence from alcohol is recommended; if you are unsure what is appropriate for your stage of disease, discuss this with your GP or specialist. For the general adult population, the UK Chief Medical Officers advise drinking no more than 14 units of alcohol per week, spread across at least three days, with alcohol-free days each week.^[14][15]

Resistance training, such as weight training or bodyweight exercises, complements aerobic activity by building muscle mass, which improves insulin sensitivity and resting metabolic rate. Sleep quality and stress management also appear to influence metabolic health: poor sleep is associated with increased visceral adiposity and insulin resistance, both of which may worsen hepatic steatosis, though these relationships are associative and the evidence base is still developing.

For people exploring structured support for weight management and metabolic health, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of clinically appropriate options may be considered. Addressing liver health is best approached as part of a sustained, whole-lifestyle strategy rather than any single intervention.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
2. Advice on physical activity, diet and alcohol | Liver disease (QS152).
3. QS152 Briefing paper – exercise reduces liver fat content.
4. Non-alcoholic fatty liver disease (NAFLD).
5. Physical activity guidelines: UK Chief Medical Officers' report.
6. UK Chief Medical Officers' physical activity guidelines (detail page).
7. Physical activity guidelines for adults aged 19 to 64.
8. Non-invasive tests for diagnosing NAFLD in adults – NICE research recommendation.
9. NICE GID-TA11477 draft scope post-referral – no medicines approved for MASLD/MASH in the UK.
10. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
11. Liver disease: applying All Our Health.
12. Low blood sugar (hypoglycaemia).
13. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis (Promrat K et al.).
14. Drink less alcohol – Better Health.
15. Delivering better oral health – Chapter 12: alcohol.
16. Effects of Mediterranean diet, exercise, and their combination on MASLD/MASH (Arita VA et al.).
17. Mediterranean Diet and Metabolic Outcomes in NAFLD (Valenzuela-Fuenzalida JJ et al.).

Frequently Asked Questions